Tiblio
Sign Up

SCNI

Scinai Immunotherapeutics Ltd
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$1.37M
P/E Ratio
0.15
EPS
$1.75
Beta
2.11
52W High
$2.41
52W Low
$0.24
50-Day MA
$0.45
200-Day MA
$0.83
Dividend Yield
—
Profit Margin
-261.40%
Forward P/E
—
PEG Ratio
—

About Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a comprehensive clinical pipeline that aims to deliver transformative therapies to enhance patient outcomes. With a seasoned leadership team and a strong commitment to rigorous research, the company is poised to capitalize on the increasing demand for advanced immunotherapeutics in the global healthcare sector. Strategic partnerships further augment Scinai's growth potential, positioning it as a significant contender within the biopharmaceutical industry.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$1.21M
Gross Profit (TTM)$-4.00M
EBITDA$-6.92M
Operating Margin-504.00%
Return on Equity-29.20%
Return on Assets-35.80%
Revenue/Share (TTM)$0.43
Book Value$1.74
Price-to-Book0.23
Price-to-Sales (TTM)1.13
EV/Revenue6.23
EV/EBITDA1.13
Quarterly Earnings Growth (YoY)87.20%
Quarterly Revenue Growth (YoY)-16.60%
Shares Outstanding$5.17M
Float$3.02M
% Insiders0.00%
% Institutions1.58%

Historical Volatility

HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—

Latest News

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.

PRNewsWire6/10/2026Neutral
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands.

PRNewsWire5/15/2026Neutral
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs JERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd.

PRNewsWire4/24/2026Neutral

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/SAMGNAmgen IncTMOThermo Fisher Scientific IncGILDGilead Sciences IncABTAbbott Laboratories
View all HEALTHCARE stocks →
Data last updated: 7/9/2026